Literature DB >> 12202311

Treatment of advanced non-small cell lung cancer.

Heine H Hansen.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12202311      PMCID： PMC1123980          DOI： 10.1136/bmj.325.7362.452

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Non-small-cell lung cancer--stalemate or progress?

Authors:  D N Carney; H H Hansen
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  Managing poor performance non-small-cell lung cancer patients.

Authors:  R Rosell
Journal:  Ann Oncol       Date:  2001-12       Impact factor: 32.976

3.  Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis.

Authors:  R S Pritchard; S P Anthony
Journal:  Ann Intern Med       Date:  1996-11-01       Impact factor: 25.391

Review 4.  Palliative radiotherapy regimens for non-small cell lung cancer.

Authors:  F Macbeth; E Toy; B Coles; A Melville; A Eastwood
Journal:  Cochrane Database Syst Rev       Date:  2001

5.  Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis.

Authors:  P Marino; A Preatoni; A Cantoni
Journal:  Cancer       Date:  1995-08-15       Impact factor: 6.860

6.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis.

Authors:  P J Souquet; F Chauvin; J P Boissel; R Cellerino; Y Cormier; P A Ganz; S Kaasa; J L Pater; E Quoix; E Rapp
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

Review 7.  Chemotherapy for non-small cell lung cancer.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2000

8.  Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

Authors:  F V Fossella; R DeVore; R N Kerr; J Crawford; R R Natale; F Dunphy; L Kalman; V Miller; J S Lee; M Moore; D Gandara; D Karp; E Vokes; M Kris; Y Kim; F Gamza; L Hammershaimb
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

9.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

10.  Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial.

Authors:  Stephen J Falk; David J Girling; Roger J White; Penelope Hopwood; Angela Harvey; Wendi Qian; Richard J Stephens
Journal:  BMJ       Date:  2002-08-31
  10 in total
  13 in total

1.  Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer.

Authors:  Ai-Gui Jiang; Hong-Lin Chen; Hui-Yu Lu
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-26       Impact factor: 4.553

2.  Adjuvant effects of fermented red ginseng extract on advanced non-small cell lung cancer patients treated with chemotherapy.

Authors:  Shu-Long Jiang; Hong-Jie Liu; Zhao-Chun Liu; Ning Liu; Rui Liu; Young-Reep Kang; Joong-Gu Ji; Chao Zhang; Bao-Jin Hua; Shin-Jyung Kang
Journal:  Chin J Integr Med       Date:  2015-07-04       Impact factor: 1.978

3.  Correlation study and significance of the EGFR expression in serum, lymph nodes and tumor tissue of NSCLC.

Authors:  Yinling Zhuo; Qisen Guo; Pingping Song; Qiong Zhang; Chen Guo; Hongsheng Zeng; Yan Guan; Xiuju Liu; Chenqing Zhao
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

4.  Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.

Authors:  Leina Sun; Qiang Zhang; Huanling Luan; Zhongli Zhan; Changli Wang; Baocun Sun
Journal:  J Exp Clin Cancer Res       Date:  2011-03-17

5.  Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer.

Authors:  Min Zhang; Xin Zhang; Chun-Xue Bai; Xian-Rang Song; Jie Chen; Lei Gao; Jie Hu; Qun-Ying Hong; Malcolm J West; Ming Q Wei
Journal:  Genet Vaccines Ther       Date:  2005-06-30

6.  A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC).

Authors:  E Senkus-Konefka; R Dziadziuszko; E Bednaruk-Młyński; A Pliszka; J Kubrak; A Lewandowska; K Małachowski; M Wierzchowski; M Matecka-Nowak; J Jassem
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

7.  Neuropilin 1 expression correlates with the Radio-resistance of human non-small-cell lung cancer cells.

Authors:  Juan Cong Dong; Hui Gao; Si Yao Zuo; Hai Qin Zhang; Gang Zhao; Shi Long Sun; Hai Ling Han; Lin Lin Jin; Li Hong Shao; Wei Wei; Shun Zi Jin
Journal:  J Cell Mol Med       Date:  2015-07-06       Impact factor: 5.310

8.  Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy.

Authors:  Chuangzhou Rao; Qiongge Hu; Jianhua Ma; Jian Li; Chen Zhang; Li Shen; Qichun Wei
Journal:  J Exp Clin Cancer Res       Date:  2010-01-22

9.  Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.

Authors:  Shu-Yan Han; Hui-Rong Ding; Wei Zhao; Fei Teng; Ping-Ping Li
Journal:  BMC Complement Altern Med       Date:  2014-05-22       Impact factor: 3.659

10.  Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.

Authors:  Feng Jin; Hui Zhu; Zheng Fu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-05-19       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.